Cargando…

Costs of a successful public-private partnership for TB control in an urban setting in Nepal

BACKGROUND: In South Asia a large number of patients seek treatment for TB from private practitioners (PPs), and there is increasing international interest in involving PPs in TB control. To evaluate the feasibility, effectiveness and costs of public-private partnerships (PPPs) for TB control, a PPP...

Descripción completa

Detalles Bibliográficos
Autores principales: Karki, Deepak K, Mirzoev, Tolib N, Green, Andrew T, Newell, James N, Baral, Sushil C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1888703/
https://www.ncbi.nlm.nih.gov/pubmed/17511864
http://dx.doi.org/10.1186/1471-2458-7-84
_version_ 1782133695016075264
author Karki, Deepak K
Mirzoev, Tolib N
Green, Andrew T
Newell, James N
Baral, Sushil C
author_facet Karki, Deepak K
Mirzoev, Tolib N
Green, Andrew T
Newell, James N
Baral, Sushil C
author_sort Karki, Deepak K
collection PubMed
description BACKGROUND: In South Asia a large number of patients seek treatment for TB from private practitioners (PPs), and there is increasing international interest in involving PPs in TB control. To evaluate the feasibility, effectiveness and costs of public-private partnerships (PPPs) for TB control, a PPP was developed in Lalitpur municipality, Nepal, where it is estimated that 50% of patients with TB are managed in the private sector. From the clinical perspective the PPP was shown to be effective. The aim of this paper is to assess and report on the costs involved in the PPP scheme. METHODS: The approach to costing took a comprehensive view, with inclusion of costs not only incurred by health facilities but also social costs borne by patients and their escorts. Semi-structured questionnaires and guided interviews were used to collect start-up and recurrent costs for the scheme. RESULTS: Overall costs for treating a TB patient under the PPP scheme averaged US$89.60. Start-up costs per patient represented 12% of the total budget. Half of recurrent costs were incurred by patients and their escorts, with institutional costs representing most of the rest. Female patients tended to spend more and patients referred from the private sector had the highest reported costs. CONCLUSION: Treating TB patients in the PPP scheme had a low additional cost, while doubling the case notification rate and maintaining a high success rate. Costs incurred by patients and their escorts were the largest contributors to the overall total. This suggests a focus for follow-up studies and for cost-minimisation strategies.
format Text
id pubmed-1888703
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18887032007-06-06 Costs of a successful public-private partnership for TB control in an urban setting in Nepal Karki, Deepak K Mirzoev, Tolib N Green, Andrew T Newell, James N Baral, Sushil C BMC Public Health Research Article BACKGROUND: In South Asia a large number of patients seek treatment for TB from private practitioners (PPs), and there is increasing international interest in involving PPs in TB control. To evaluate the feasibility, effectiveness and costs of public-private partnerships (PPPs) for TB control, a PPP was developed in Lalitpur municipality, Nepal, where it is estimated that 50% of patients with TB are managed in the private sector. From the clinical perspective the PPP was shown to be effective. The aim of this paper is to assess and report on the costs involved in the PPP scheme. METHODS: The approach to costing took a comprehensive view, with inclusion of costs not only incurred by health facilities but also social costs borne by patients and their escorts. Semi-structured questionnaires and guided interviews were used to collect start-up and recurrent costs for the scheme. RESULTS: Overall costs for treating a TB patient under the PPP scheme averaged US$89.60. Start-up costs per patient represented 12% of the total budget. Half of recurrent costs were incurred by patients and their escorts, with institutional costs representing most of the rest. Female patients tended to spend more and patients referred from the private sector had the highest reported costs. CONCLUSION: Treating TB patients in the PPP scheme had a low additional cost, while doubling the case notification rate and maintaining a high success rate. Costs incurred by patients and their escorts were the largest contributors to the overall total. This suggests a focus for follow-up studies and for cost-minimisation strategies. BioMed Central 2007-05-18 /pmc/articles/PMC1888703/ /pubmed/17511864 http://dx.doi.org/10.1186/1471-2458-7-84 Text en Copyright © 2007 Karki et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Karki, Deepak K
Mirzoev, Tolib N
Green, Andrew T
Newell, James N
Baral, Sushil C
Costs of a successful public-private partnership for TB control in an urban setting in Nepal
title Costs of a successful public-private partnership for TB control in an urban setting in Nepal
title_full Costs of a successful public-private partnership for TB control in an urban setting in Nepal
title_fullStr Costs of a successful public-private partnership for TB control in an urban setting in Nepal
title_full_unstemmed Costs of a successful public-private partnership for TB control in an urban setting in Nepal
title_short Costs of a successful public-private partnership for TB control in an urban setting in Nepal
title_sort costs of a successful public-private partnership for tb control in an urban setting in nepal
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1888703/
https://www.ncbi.nlm.nih.gov/pubmed/17511864
http://dx.doi.org/10.1186/1471-2458-7-84
work_keys_str_mv AT karkideepakk costsofasuccessfulpublicprivatepartnershipfortbcontrolinanurbansettinginnepal
AT mirzoevtolibn costsofasuccessfulpublicprivatepartnershipfortbcontrolinanurbansettinginnepal
AT greenandrewt costsofasuccessfulpublicprivatepartnershipfortbcontrolinanurbansettinginnepal
AT newelljamesn costsofasuccessfulpublicprivatepartnershipfortbcontrolinanurbansettinginnepal
AT baralsushilc costsofasuccessfulpublicprivatepartnershipfortbcontrolinanurbansettinginnepal